Peptide content raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography together with mass spectrometry. The chromatogram provides a purity estimate as a percentage of total peak area, while the mass spectrum confirms that the observed mass matches the expected value. Amino acid analysis or tandem mass spectrometry sequencing can provide additional confirmation. Reported purity figures depend on the column, gradient, and detection wavelength, so values from different laboratories are not directly comparable without method details.
Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.
=== Development of the concept === In 1893, the American botanist Charles Reid Barnes proposed two terms, photosyntax and photosynthesis, for the biological process of synthesis of complex carbon compounds out of carbonic acid, in the presence of chlorophyll, under the influence of light. The term photosynthesis is derived from the Greek phōs (φῶς, 'gleam') and sýnthesis (σύνθεσις, 'arranging together'), while photosyntax comes from sýntaxis (σύνταξις, 'configuration'). Over time, the term photosynthesis came into common usage. Later discovery of anoxygenic photosynthetic bacteria and photophosphorylation necessitated redefinition of the term.
==== Fibrous astrocytes ==== The fibrous astrocytes are usually located within white matter, have relatively few organelles, and exhibit long unbranched cellular processes. This type often has astrocyte endfeet processes that physically connect the cells to the outside of capillary walls when they are in proximity to them.
==== Choanoflagellate Salpingoeca rosetta ==== (also known as Choanoflagellate Proterospongia) The choanoflagellate Salpingoeca rosetta is a rare freshwater eukaryote consisting of a number of cells embedded in a jelly-like matrix. This organism demonstrates a very primitive level of cell differentiation and specialization. This is seen with flagellated cells and their collar structures that move the cell colony through the water, while the amoeboid cells on the inside serve to divide into new cells to assist in colony growth. Similar low level cellular differentiation and specification can also be seen in sponges. They also have collar cells (also called choanocytes due to their similarities to choanoflagellates) and amoeboid cells arranged in a gelatinous matrix. Unlike choanoflagellate Salpingoeca rosetta, sponges also have other cell-types that can perform different functions (see sponges). Also, the collar cells of sponges beat within canals in the sponge body, whereas Salpingoeca rosetta’s collar cells reside on the inside; it lacks internal canals. Despite these minor differences, there is strong evidence that Proterospongia and animals are highly related.
=== Carl Hardee Sr. campaign === In March 2017, Hardee's began to move away from the sexualized ads by releasing a commercial featuring a white bearded character played by Charles Esten as "Carl Hardee Sr." who had come back into the office (much to the delight of the employees) to find his son (Drew Tarver), a.k.a. "Carl Jr." who was focusing on sex appeal over its food. The commercial marked a turning point in CKE's advertising, as the company wanted to move away from its provocative ads and focus more on food and as a competitor to Five Guys, Steak 'n Shake, and In-N-Out Burger. "Carl Hardee Sr." was also expected to become the new company spokesperson.
The Han Chinese have made significant contributions to various fields in the advancement and progress of human civilization, including business and economy, culture and society, governance, and science and technology, both historically and in the modern era. The invention of paper, printing, the compass and gunpowder are celebrated in Chinese society as the Four Great Inventions. The innovations of Yi Xing (683–727), a polymathic Buddhist monk, mathematician, and mechanical engineer of the Tang dynasty is acknowledged for applying the earliest-known escapement mechanism to a water-powered celestial globe. The accomplishments and advancements of the Song dynasty polymath Su Song (1020–1101) is recognized for inventing a hydro-mechanical astronomical clock tower in medieval Kaifeng, which employed an early escapement mechanism. The work of medieval Chinese polymath Shen Kuo (1031–1095) of the Song dynasty theorized that the sun and moon were spherical and wrote of planetary motions such as retrogradation as well as postulating theories for the processes of geological land formation. Medieval Han Chinese astronomers were also among the first peoples to record observations of a cosmic supernova in 1054 AD, the remnants of which would form the Crab Nebula. In the contemporary era, Han Chinese have continued to contribute to the development and growth of modern science and technology. Han Chinese Nobel Prize laureates include Tu Youyou, Steven Chu, Samuel C.C. Ting, Chen Ning Yang, Tsung-Dao Lee, Yuan T. Lee, Daniel C. Tsui, Roger Y. Tsien and Charles K.
Sources: en.wikipedia.org
== Federal trial == Following the 1981 grand jury indictment of several key IBT officials, a federal trial began on April 4, 1983, to evaluate whether IBT had committed scientific fraud. According to a May 13 article in The Wall Street Journal, "investigators charged that three big chemical companies—[Monsanto, Olin Corporation, and FMC Corporation]—knowingly submitted flawed data to the EPA in support of a widely used swimming pool chlorinator that was suspected of causing kidney and bladder problems." All three companies denied allegations of wrongdoing and reaffirmed the safety of their products. On May 25, Cornelius Garrett testified that "[no] research animals survived the entire testing period" for either Sencor or Nemacure. Garrett also testified that Smith instructed him to falsify subject data, which he said was a "common practice". Smith testified that he was himself instructed by Wright to similarly falsify data on trichlorocarbanilide tests. Calandra requested a mistrial to have cardiac surgery and received approval on July 11. Keplinger, Plank and Wright resultingly argued that they should also receive a mistrial because his absence would undermine their case, but their request was denied on July 12. Testimony included that of an attorney retained by Nalco to defend IBT, Merrill Thompson, who refused to participate during earlier investigations of the laboratory.
Natural Selection 2 is the sequel to Natural Selection. Natural Selection 2 started development using the Source Engine, but their development blog later announced [1] Archived 2011-07-20 at the Wayback Machine that Unknown Worlds had moved to the Spark engine, an engine they created themselves. Natural Selection 2 has the same basic gameplay as Natural Selection, but with new weapons and abilities. It was released commercially on Steam. According to an interview with the game director, Charlie Cleveland (Flayra), the sequel continues where the original left off and features environments that are dark and denser. Several gameplay modes once available only as community-developed mods (such as Marines vs. Marines) became officially supported. In addition, a major new feature of Natural Selection 2 is dynamic infestation [2] Archived 2006-12-23 at the Wayback Machine, released in December 2006. The proposed feature would dynamically generate bacterial infestation based on what areas of the map the alien team controlled. The alpha testing of Natural Selection 2 began on 26 July 2010. The game was released on October 30, 2012.
=== Outcome and management === The liver injury due to the carbapenems is usually mild and self-limited. Rarely, the carbapenems can cause a clinically apparent acute cholestatic hepatitis that is usually self-limiting and not requiring therapy or intervention. In patients with vanishing bile duct syndrome, corticosteroids are often used but have not been shown to be beneficial and are best avoided. Some patients may benefit from symptomatic therapy of the pruritus associated with cholestasis using antihistamines, ursodiol, or cholestyramine. Little information is available on possible cross-sensitivity to liver injury among the different betalactam antibiotics, but patients with clinically apparent liver injury due to imipenem should probably avoid the other carbapenems.
== Benefits == One of the main advantages of this method of preparing frozen food is that the freezing process takes only a few minutes. The exact time depends on the type of IQF freezer and the product. The short freezing prevents formation of large ice crystals in the product's cells, which destroys the membrane structures at the molecular level. This makes the product keep its shape, colour, smell and taste after defrost, to a far greater extent. Another advantage of IQF technology is its ability to separate units of the products during freezing, which produces a higher quality product compared to block freezing. This is important for food sustainability, as the consumer can defrost and use the exact quantity needed. A growing demand in IQF products is registered at global level due to the higher quality of these products and to the benefit of having separately frozen pieces. IQF is also a common pre-treatment for freeze-drying food because both processes preserve the size, taste and cell structure of the food better than methods such as traditional block freezing or air drying.
This led to the discovery of the same substance he had found in eight other patients. He conducted tests and found reactions that gave rise to benzaldehyde and benzoic acid, which led him to conclude that the compound contained a benzene ring. Further testing showed the melting point to be the same as phenylpyruvic acid, which indicated that the substance was in the urine. In 1954, Horst Bickel, Evelyn Hickmans and John Gerrard published a paper that described how they created a diet that was low in phenylalanine and the patient recovered. Bickel, Gerrard, and Hickmans were awarded the John Scott Medal in 1962 for their discovery. PKU was the first disorder to be routinely diagnosed through widespread newborn screening. Robert Guthrie introduced the newborn screening test for PKU in the early 1960s. With the knowledge that PKU could be detected before symptoms were evident, and treatment initiated, screening was quickly adopted around the world. Ireland was the first country to introduce a national screening programme in February 1966, Austria also started screening in 1966 and England in 1968. In 2017, the European Guidelines were published. They were called for by the patient organizations such as the European Society for Phenylketonuria and Allied Disorders Treated as Phenylketonuria. They have received some critical reception.
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.